Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells

Mu Kuan Chen, Shun Fa Yang, Jui Chung Lai, Kun Tu Yeh, Jia Sin Yang, Li Sheng Chen, Hui Chuan Chen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The role of bcl-2 expression, bcl-2 inhibitor HA14-1, and matrix metalloproteinase (MMP)-2 is still unclear in nasopharyngeal carcinoma (NPC). Methods: From 1996 to 2000, 145 patients with newly diagnosed NPC who were treated with high dose radiotherapy were enrolled. The relationship between bcl-2 expression, TNM stage, and disease-specific survival was analyzed. Furthermore, the NPC cell line HONE-1 was used to confirm the relationship between bcl-2 and cell metastasis. Results: Among the 145 patients, 47 (32.4%) of them were bcl-2 positive. The expression of bcl-2 was significantly correlated with neck lymph node metastasis (p = 0.006), and patients with negative bcl-2 expression had better disease-free survival (p = 0.007). A Cox regression model revealed that only bcl-2 expression (p = 0.023) and stage IV (p = 0.043) were statistically significant in the prognosis of NPC. In vitro analysis also showed that treatment with the bcl-2 inhibitor HA14-1 exerted an inhibitory effect on migration and expression of MMP-2 in HONE-1 cells. Conclusions: Bcl-2 expression represents an important and easily assayed prognostic factor, and it may play an important role in lymph node metastasis. Inhibition of the migration mediated by MMP-2 may be a key feature for the prevention of cancer metastasis.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalClinica Chimica Acta
Volume411
Issue number5-6
DOIs
Publication statusPublished - Mar 2 2010
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 2
Cells
Neoplasm Metastasis
Lymph Nodes
Radiotherapy
Dosimetry
Proportional Hazards Models
Disease-Free Survival
Neck
Cell Line
Survival
Nasopharyngeal carcinoma
Neoplasms
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
Therapeutics

Keywords

  • Bcl-2
  • Inhibitor
  • Matrix metalloproteinases
  • Nasopharyngeal carcinoma
  • Prognosis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. / Chen, Mu Kuan; Yang, Shun Fa; Lai, Jui Chung; Yeh, Kun Tu; Yang, Jia Sin; Chen, Li Sheng; Chen, Hui Chuan.

In: Clinica Chimica Acta, Vol. 411, No. 5-6, 02.03.2010, p. 400-405.

Research output: Contribution to journalArticle

Chen, Mu Kuan ; Yang, Shun Fa ; Lai, Jui Chung ; Yeh, Kun Tu ; Yang, Jia Sin ; Chen, Li Sheng ; Chen, Hui Chuan. / Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. In: Clinica Chimica Acta. 2010 ; Vol. 411, No. 5-6. pp. 400-405.
@article{e7f45db3a27f4faf8c1f25d3001087cf,
title = "Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells",
abstract = "Background: The role of bcl-2 expression, bcl-2 inhibitor HA14-1, and matrix metalloproteinase (MMP)-2 is still unclear in nasopharyngeal carcinoma (NPC). Methods: From 1996 to 2000, 145 patients with newly diagnosed NPC who were treated with high dose radiotherapy were enrolled. The relationship between bcl-2 expression, TNM stage, and disease-specific survival was analyzed. Furthermore, the NPC cell line HONE-1 was used to confirm the relationship between bcl-2 and cell metastasis. Results: Among the 145 patients, 47 (32.4{\%}) of them were bcl-2 positive. The expression of bcl-2 was significantly correlated with neck lymph node metastasis (p = 0.006), and patients with negative bcl-2 expression had better disease-free survival (p = 0.007). A Cox regression model revealed that only bcl-2 expression (p = 0.023) and stage IV (p = 0.043) were statistically significant in the prognosis of NPC. In vitro analysis also showed that treatment with the bcl-2 inhibitor HA14-1 exerted an inhibitory effect on migration and expression of MMP-2 in HONE-1 cells. Conclusions: Bcl-2 expression represents an important and easily assayed prognostic factor, and it may play an important role in lymph node metastasis. Inhibition of the migration mediated by MMP-2 may be a key feature for the prevention of cancer metastasis.",
keywords = "Bcl-2, Inhibitor, Matrix metalloproteinases, Nasopharyngeal carcinoma, Prognosis",
author = "Chen, {Mu Kuan} and Yang, {Shun Fa} and Lai, {Jui Chung} and Yeh, {Kun Tu} and Yang, {Jia Sin} and Chen, {Li Sheng} and Chen, {Hui Chuan}",
year = "2010",
month = "3",
day = "2",
doi = "10.1016/j.cca.2009.12.010",
language = "English",
volume = "411",
pages = "400--405",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "5-6",

}

TY - JOUR

T1 - Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells

AU - Chen, Mu Kuan

AU - Yang, Shun Fa

AU - Lai, Jui Chung

AU - Yeh, Kun Tu

AU - Yang, Jia Sin

AU - Chen, Li Sheng

AU - Chen, Hui Chuan

PY - 2010/3/2

Y1 - 2010/3/2

N2 - Background: The role of bcl-2 expression, bcl-2 inhibitor HA14-1, and matrix metalloproteinase (MMP)-2 is still unclear in nasopharyngeal carcinoma (NPC). Methods: From 1996 to 2000, 145 patients with newly diagnosed NPC who were treated with high dose radiotherapy were enrolled. The relationship between bcl-2 expression, TNM stage, and disease-specific survival was analyzed. Furthermore, the NPC cell line HONE-1 was used to confirm the relationship between bcl-2 and cell metastasis. Results: Among the 145 patients, 47 (32.4%) of them were bcl-2 positive. The expression of bcl-2 was significantly correlated with neck lymph node metastasis (p = 0.006), and patients with negative bcl-2 expression had better disease-free survival (p = 0.007). A Cox regression model revealed that only bcl-2 expression (p = 0.023) and stage IV (p = 0.043) were statistically significant in the prognosis of NPC. In vitro analysis also showed that treatment with the bcl-2 inhibitor HA14-1 exerted an inhibitory effect on migration and expression of MMP-2 in HONE-1 cells. Conclusions: Bcl-2 expression represents an important and easily assayed prognostic factor, and it may play an important role in lymph node metastasis. Inhibition of the migration mediated by MMP-2 may be a key feature for the prevention of cancer metastasis.

AB - Background: The role of bcl-2 expression, bcl-2 inhibitor HA14-1, and matrix metalloproteinase (MMP)-2 is still unclear in nasopharyngeal carcinoma (NPC). Methods: From 1996 to 2000, 145 patients with newly diagnosed NPC who were treated with high dose radiotherapy were enrolled. The relationship between bcl-2 expression, TNM stage, and disease-specific survival was analyzed. Furthermore, the NPC cell line HONE-1 was used to confirm the relationship between bcl-2 and cell metastasis. Results: Among the 145 patients, 47 (32.4%) of them were bcl-2 positive. The expression of bcl-2 was significantly correlated with neck lymph node metastasis (p = 0.006), and patients with negative bcl-2 expression had better disease-free survival (p = 0.007). A Cox regression model revealed that only bcl-2 expression (p = 0.023) and stage IV (p = 0.043) were statistically significant in the prognosis of NPC. In vitro analysis also showed that treatment with the bcl-2 inhibitor HA14-1 exerted an inhibitory effect on migration and expression of MMP-2 in HONE-1 cells. Conclusions: Bcl-2 expression represents an important and easily assayed prognostic factor, and it may play an important role in lymph node metastasis. Inhibition of the migration mediated by MMP-2 may be a key feature for the prevention of cancer metastasis.

KW - Bcl-2

KW - Inhibitor

KW - Matrix metalloproteinases

KW - Nasopharyngeal carcinoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=74849087093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849087093&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2009.12.010

DO - 10.1016/j.cca.2009.12.010

M3 - Article

VL - 411

SP - 400

EP - 405

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 5-6

ER -